sorafenib has been researched along with aztreonam in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (aztreonam) | Trials (aztreonam) | Recent Studies (post-2010) (aztreonam) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 213 | 0 | 32 |
| Protein | Taxonomy | sorafenib (IC50) | aztreonam (IC50) |
|---|---|---|---|
| Beta-lactamase | Escherichia coli | 0.032 | |
| Penicillin-binding protein 1A | Pseudomonas aeruginosa PAO1 | 3.34 | |
| Efflux transporter | Salmonella enterica subsp. enterica serovar Newport | 0.006 | |
| Beta-lactamase | Klebsiella pneumoniae | 0.006 | |
| AmpC | Escherichia coli | 0.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for sorafenib and aztreonam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |